Engineering a denaturant-resistant polymerase for direct nucleic acid diagnostics

设计用于直接核酸诊断的抗变性聚合酶

基本信息

批准号：
10308721
负责人：
Barry Ryan Lutz
金额：
$ 18.46万
依托单位：
UNIVERSITY OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-12-01 至 2022-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10308721
关键词：
Address Automation Biological Biological Assay Biological Models Biophysics Buffers Cells Chemicals Clinic Clinical Communicable Diseases Complex Coronavirus Cytolysis DNA Detection Development Diagnosis Diagnostic Directed Molecular Evolution Disease Outbreaks Drops Ebola Engineering Environment Enzymes Equipment Excision Exposure to Genetic Diseases Genome Goals Guidelines HIV HIV-1 Hepatitis Viruses Human Human immunodeficiency virus test Influenza Laboratories Lateral Libraries Liquid substance Measles Mediating Methods Microfluidics Modeling Mutagenesis Mutation Nucleic Acid Amplification Tests Nucleic Acids Patients Peptide Hydrolases Plasma Poliomyelitis Polymerase Preparation Procedures Proteins Public Health RNA RNA Viruses RNA purification Rabies Resistance Resolution Resource-limited setting Resources Reverse Transcription Ribonucleases Robotics Sampling Structure Testing Time Tube Variant Virion Virus Vision Work amplification detection cancer type communicable disease diagnosis cost design detection method disease diagnostic guanidine thiocyanate health care settings human tissue inhibitor insight instrument instrumentation isothermal amplification low income country macromolecule molecular dynamics mutant mutation screening nucleic acid purification point of care point-of-care diagnostics pressure rational design self testing stem tool viral RNA

项目摘要

Project Abstract Nucleic acid amplification tests (NAATs) are powerful tools for infectious disease diagnostics. While NAATs are routinely used in the clinic, their use in point-of-care (POC) contexts is constrained by complex procedures needed to extract and purify nucleic acids from patient samples. This is especially troublesome for RNA targets, due to the fragility of RNA and abundance of RNA-degrading ribonucleases in samples and the environment. Nevertheless, RNA viruses are key targets for POC diagnostics, as they are abundant in low- resource settings (e.g. low-income countries, where roughly 20 million HIV patients live) or in settings where fast turnaround and patient self-testing are useful (e.g. outbreaks of airborne viruses such as influenza and coronavirus). Thus, simpler approaches to RNA sample preparation are needed in POC-NAAT contexts. Much of the complexity of NAAT sample preparation stems from the paradoxical need to add chaotropes to extract nucleic acids, then remove chaotropes before amplification. Chaotropes, such as guanidinium thiocyanate (GuSCN), are chemical denaturants that disrupt the structure of biological macromolecules. They are used in NAAT sample preparation to lyse target virions/cells and denature inhibitors, such as ribonucleases and proteases. Chaotropes are effective, but also inhibit polymerase activity, so they must be removed before amplification. Many POC adaptations of NAAT workflows involve robotic or microfluidic automation of chaotrope addition and removal, but still require specialized equipment and/or laboratory resources. We will address the POC-NAAT sample preparation bottleneck in a different way: instead of automating chaotrope removal, we will eliminate the need for it. We propose to engineer a polymerase to be “chaostable”, or active in a chaotropic amplification buffer, enabling simultaneous extraction, amplification, and detection of viral RNA targets in a single tube. To realize this vision, we propose three specific aims, using a starting polymerase previously developed by our lab and HIV-1 as a model RNA target. Aim 1: Develop a chaostable polymerase via compartmentalized self-replication in chaotropic conditions. We will use a high-throughput directed evolution approach to develop a polymerase that retains activity in 3M GuSCN (the minimum recommended concentration for RNA extraction buffers). Aim 2: Investigate mechanisms of polymerase chaotrope resistance via deep mutational scanning and molecular dynamics simulations. We will use deep mutational scanning and molecular dynamics simulations to study interactions of GuSCN on our polymerase and identify rational design methods for GuSCN resistance. Aim 3: Incorporate chaostable polymerase into a proof-of-concept HIV diagnostic that performs sample lysis, RT-LAMP amplification, and colorimetric detection in a single tube. Using the best-performing chaostable polymerases developed in Aims 1 and 2, we will design a single-tube RT-LAMP assay for HIV, and test it against pure HIV RNA and HIV patient plasma samples.